Company Overview and News

9
Bellatrix Announces Second Quarter 2018 Conference Call and Webcast Details

2018-07-25 globenewswire - 1
CALGARY, Alberta, July 25, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix” or the “Company”) (TSX:BXE) (NYSE:BXE) plans to release its second quarter 2018 operational and financial results after markets close on August 2, 2018. Additionally, Bellatrix will host a conference call to discuss the second quarter results on August 2, 2018 at 3:30 pm MT / 5:30 pm ET. To participate, please call toll-free 1-800-319-4610, or 403-351-0324, or 416-915-3239.
BXE BXE

7
Bellatrix Provides an Operational Update and Announces Renewal and Extension of Its Revolving Credit Facilities

2018-06-04 globenewswire
CALGARY, Alberta, June 04, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix", "our" or the "Company") (TSX:BXE) (NYSE:BXE) provides an operational update and announces the renewal and extension of its revolving credit facilities.
BXE BXE

8
Bellatrix Reports Voting Results From 2018 Annual and Special Meeting

2018-05-10 globenewswire - 1
CALGARY, Alberta, May 09, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix” or the “Company”) (TSX:BXE) (NYSE:BXE) is pleased to announce the voting results from its annual and special meeting of shareholders held May 9, 2018 in Calgary, Alberta (the “Meeting”).
BXE BXE

7
Bellatrix Reminds Shareholders of Voting Cut-Off for Upcoming Shareholder Meeting and First Quarter Conference Call and Webcast Details

2018-05-07 globenewswire
CALGARY, Alberta, May 07, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix” or the “Company”) (TSX:BXE) (NYSE:BXE) would like to remind shareholders they have until 3:00 pm (Calgary Time) on Monday May 7, 2018 to vote their shares for the upcoming Annual and Special Meeting (the “Meeting”) of Bellatrix shareholders to be held 3:00 pm (Calgary Time) on Wednesday May 9, 2018.
BXE BXE

7
Bellatrix Announces Acquisition and Retirement of US$10 Million of Its Senior Unsecured Notes Due 2020

2018-05-02 globenewswire
CALGARY, Alberta, May 02, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix” or the “Company”) (TSX:BXE) (NYSE:BXE) today announces that it has entered into an exchange agreement with a holder (the "Holder") of its 8.50% senior unsecured notes due May 15, 2020 (the “Senior Notes”) to exchange in a privately negotiated transaction, US$10 million aggregate principal amount of the Senior Notes for 7,081,837 common shares of Bellatrix.
BXE DTK BXE

7
Bellatrix Announces First Quarter 2018 Conference Call and Webcast Details and Reminder of Upcoming Annual General Meeting

2018-04-24 globenewswire
CALGARY, Alberta, April 24, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix” or the “Company”) (TSX:BXE) (NYSE:BXE) plans to release its first quarter operational and financial results after markets close on May 8, 2018. Additionally, Bellatrix will host a conference call to discuss the first quarter results on May 9, 2018 at 9:00 am MT / 11:00 am ET. To participate, please call toll-free 1-800-319-4610, or 403-351-0324, or 416-915-3239.
BXE BXE

7
Bellatrix Announces Alder Flats Plant Phase 2 Start-Up, Updated Commodity Risk Management Contracts and Updated 2018 Guidance

2018-04-03 globenewswire
CALGARY, Alberta, April 03, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix”, “we”, “our” or the “Company”) (TSX:BXE) (NYSE:BXE) announces the start-up of the Phase 2 expansion project at the Bellatrix O’Chiese Nees-Ohpawganu’ck deep-cut gas plant at Alder Flats (the “Alder Flats Plant”), an update of commodity risk management contracts, and revised 2018 corporate guidance.
BXE BXE

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...